Pooled analysis of trials in 2356 patients with HeFH or ASCVD: obicetrapib 10 mg daily for 12 weeks reduced Lp(a) by 37.3% (14.9 nmol/L) vs placebo, alongside LDL-C −37.0% and apoB −21.3%. Absolute Lp(a) falls were similar at baseline ≥150 vs 50–<150 nmol/L.
Secondary analysisn = 2,356
Nicholls et al. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials